Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-313 Given as a Single Intratympanic Injection in Subjects With Subjective Tinnitus
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Gacyclidine (Primary)
- Indications Tinnitus
- Focus Adverse reactions; Proof of concept
- Sponsors Otonomy [CEASED]
- 25 Feb 2022 According to an Otonomy media release, company will host a virtual Investor R&D Event on March 22, 2022 and will review data from this trial.
- 12 Oct 2021 Results presented in an Otonomy Media Release.
- 12 Oct 2021 According to an Otonomy media release, results were published in Otology & Neurotology, a leading peer-reviewed journal in otolaryngology.